HC Reform Update from Mark Sanna: The specialty pharmaceutical company Allergan has agreed to pay $600 million to settle civil and criminal accusations that it illegally marketed Botox, the drug used in antiwrinkle injections, for medical uses for which the drug had not been approved. Allergan, based in Irvine, Calif., also agreed to pay $225 million to resolve civil charges that it had caused false claims to be submitted to Medicare and Medicaid. “The significance of the case is that Allergan promoted Botox for off-label uses, uses that were not approved by the F.D.A. as being safe and effective,” said Marcella Auerbach, a lawyer representing two whistle-blowers in the case.